BioPharmas R&D, Marketing teams and Drug Safety Departments The need to monitor, in an efficient and comparative manner, is paramount for pharmas. It goes beyond ensuring the ongoing safety of drugs after they are released to the market. Comparative studies and patient-focused recommendations are used as a way to increase products market penetration, as well as to assess critical decisions on a 10-years long drug development journey In essence, life-science analytics’ growing need within the pharmaceutical industry has three main reasons: The growing impact of patients on healthcare systems, medication and treatment adherence The impact on the health of individuals, (safety & pharmacovigilance) The impact to the pharmaceutical company as a whole (strategy & marketing) Data2Life’s life science analytics, features structured and unstructured AI-guided text analysis. Our automation processes provide pharma departments with greater efficiency, reduce error-prone tasks, free resources for higher value-creation tasks, while avoiding any compromise on meeting regulatory obligations. Life Sciences Analytics, CROs and Healthcare IT Partnerships CROs (Clinical Research Organizations) and life-sciences analytics companies have to face a complex challenge: supporting and fueling the pharma innovation. This demand may also take the simple form of automating lengthy processes or generating IT cost-savings and public -cloud migration. CROs & life-sciences analytics companies are partnering with Data2Life to help delivering innovative solutions, using our machine-learning and big-data proficiency. From our partners’ perspective, the gain is vital: they can focus on keeping their customers’ happy and increase their stickiness in the pharma value-chain. When dealing with healthcare big-data and Artificial Intelligence no partner is alike! The diversity of needs is driven by diverging parameters such as: therapeutic focus, end-users, ad-hoc needs, or offering complementary. In this domain, a young and dynamic healthcare start-up such as Data2Life presents clear advantages: beyond the technological-edge, our partners leverage our flexibility, our speed of development and internal agility to accelerate their time-to-market and optimize the market-fit adjustments. Health Authorities, Regulatory Affairs and Safety Research Teams Safety research teams’ post market surveillance studies are often produced based on the analysis of limited data sets available during clinical trials. Real world datasets are a first positive step that allow to considerably improve the production of safety studies while reducing the size of the patient cohort used and the time required to obtain relevant results. However, this is not enough – filling the gap to achieving scientific evidence is mandatory. In this domain, regulatory bodies and health authorities are already using Data2Life’s products – the outcome has been overwhelming: not only has the effectiveness been dramatically higher, but the post-market surveillance coverage and depth of analysis has raised to unprecedented levels., All in all, our regulatory affairs and health authorities customers are claiming that Data2Life products and reports result in a considerable RoI boost – delivered in the form of costs’ cut-down and a greater span of the protected patient population. Healthcare Providers, Health Insurance and Economic Units Pharmacy and Therapeutics (P&T) committees are responsible for defining the formulary of a hospital/health plan while making decisions on what drugs are allowed to be dispensed and in what circumstances specific drugs should be used. This process involves a constant comparison of drugs that relies on limited data received from pharmaceutical representatives, anecdotal evidence provided by physicians and literature. Data2Life’s life science analytics technology supplies healthcare providers, pharmas and global medical affairs teams with real world evidence from their own patients and compares that to data from other hospitals and sources from around the world. This allows healthcare providers to make better decisions which will eventually result in saved time, improved patient outcomes, and savings in adverse event related costs. Moreover, Data2Life aims to solve the challenge affecting the ‘point of care’, in the closest timeframe to patient and caregiver interaction. This is achieved by simplifying the overwhelming amount of safety information about drugs and enabling physicians in making quick, informed prescribing decisions.